Edwards Lifesciences Corporation (NYSE:EW) issued its quarterly earnings data on Tuesday. The medical research company reported $0.84 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02), RTT News reports. The business had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. Edwards Lifesciences Corporation’s revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.68 earnings per share. Edwards Lifesciences Corporation updated its Q4 guidance to $0.84-0.94 EPS.

Edwards Lifesciences Corporation (NYSE:EW) traded up 0.12% on Tuesday, reaching $114.25. 2,326,660 shares of the company traded hands. The firm has a 50 day moving average price of $111.17 and a 200 day moving average price of $112.34. The stock has a market capitalization of $24.12 billion, a price-to-earnings ratio of 34.65 and a beta of 0.62. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. In the last three months, insiders sold 201,161 shares of company stock valued at $22,826,072. 2.13% of the stock is currently owned by company insiders.

A number of brokerages recently commented on EW. Canaccord Genuity reissued a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Cowen and Company reaffirmed a “buy” rating and set a $135.00 price target on shares of Edwards Lifesciences Corporation in a research note on Thursday, October 12th. BidaskClub cut shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Bank of America Corporation raised their price target on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Edwards Lifesciences Corporation presently has an average rating of “Buy” and an average price target of $120.75.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Issues Earnings Results, Misses Expectations By $0.02 EPS” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/24/edwards-lifesciences-corporation-ew-issues-earnings-results-misses-expectations-by-0-02-eps.html.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.